Physician profile
Daniel B Fried
NPI 1295842045
$57,071.78
in general payments reported to CMS, 2019-2025
29 companies · $17K in 2025
The $17K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,687 · 2020: $15K · 2021: $328 · 2022: $2,786 · 2023: $816 · 2024: $18K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $4,286 · Food and Beverage: $3,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,272.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,208.21 |
| Travel and Lodging | $4,286.16 |
| Food and Beverage | $3,397.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50,790.53 | 2019-2025 | Spaceoar System, Spaceoar Vue System - 10ml, General - Therapies |
| Bioprotect Medical, INC. | $4,777.59 | 2024-2025 | Bioprotect Balloon Implant System |
| Gt Medical Technologies, INC | $264.82 | 2021-2022 | |
| Novocure INC. | $137.11 | 2019 | |
| Elekta, INC. | $132.79 | 2019-2021 | |
| Amgen INC. | $123.03 | 2019-2020 | |
| Eisai INC. | $110.45 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $99.11 | 2024 | Orgovyx |
| Incyte Corporation | $70.31 | 2019-2020 | |
| Varian Medical Systems, INC. | $60.55 | 2020 | |
| Brainlab, INC. | $45.86 | 2023 | Image Guided Surgical Device |
| Janssen Biotech, INC. | $44.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.96 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $38.64 | 2019-2024 | Provenge |
| Celgene Corporation | $36.44 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.23 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $33.86 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $33.55 | 2019-2020 | |
| Astellas Pharma US INC | $27.39 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $25.88 | 2019 | |
| Kyowa Kirin, INC. | $24.06 | 2019 | |
| Genzyme Corporation | $23.91 | 2019-2020 | |
| Genentech USA, INC. | $23.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.19 | 2019 | |
| Puma Biotechnology, INC. | $13.57 | 2020 | |
| Biocompatibles, INC. | $13.50 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.61 | 2019 | |
| Secura Bio, INC. | $11.45 | 2019 | |
| Sirtex Medical INC | $7.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Fried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.